Table 3 Timing of study procedures

Time window (+/- days)

+/-2

+/-7

+/-14

+/-21

+/-21

+/-21

+/-21

+/-21

Demographics

X

Medical history

X

Donor & transplantation related information

X

Dialysis information

X

X

X

X

Vital signs - Height (only at baseline), blood pressure, weight, heart rate

X

X

X

X

X

X

X

X

X

Trough levels CNI/EVR

X

X

X

X

X

X

X

X

Haematology - Hb, Ht, MCV, leucocytes + differentiation, platelets

X

X

X

X

X

X

X

X

Biochemistry - Creatinine, sodium, potassium, albumin, calcium, phosphate, glucose, HbA1c

X

X

X

X

X

X

X

X

Lipid Profile - Cholesterol (total, HDL and LDL) and triglycerides

X

X

X

X

X

X

X

24 hour Urine - Protein, sodium, creatinine clearance

X

X

X

Spot urine - Creatinine, protein

X

X

X

X

X

X

X

X

Virology – Cytomegalovirus PCR, BK-virus PCR

X

X

X

Biobanking – 10 ml EDTA, 10 ml serum, 8 ml urine (urine not at baseline)

X

X

X

X

Optional: PBMCs – 3 x 10 ml lithium heparin (+ lymphocyte subset)

X

X

X

DSA

X

X

X

Tests and questionnaires 1 - Grip strength, CFS, SF-12, EQ-5D, B-IPQ, DSI + MTSOSD-59

X

X

X

Tests and questionnaires 2 – FFI, SPPB, MoCA, BAASIS

X

X

Secondary endpoint status

X

X

X

X

X

X

X

X

Study medication status

X

X

X

X

X

X

X

X

Concomitant medication

X

X

X

X

X

X

X

X

X

Adverse events

X

X

X

X

X

X

X

X

X